Decreased Serum Dickkopf-1 Levels After Hypoglycemic Therapy in Patients with Type 2 Diabetes Mellitus

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2022 Sep 12

PMID 36091484

Authors

Fei Gao

Cheng Li

Jiahui Peng

Wei Lu

Wei Zhu

Jian Zhou

Jingyi Lu

Xiaojing Ma

Affiliations

Soon will be listed here.

Abstract

Aim: Dickkopf-1 (DKK-1) is a major inhibitor of Wingless protein signaling pathway, which is involved in glucose metabolism and cardiovascular diseases. The aim of the study was to investigate the changes of serum DKK-1 levels after hypoglycemic treatments and the relationship between DKK-1 and clinical parameters.

Materials And Methods: The study was a sub-study of a previously published clinical trial (the effect of Acarbose on glycemic variability in patients with type 2 diabetes mellitus using premixed insulin compared to metformin). All subjects underwent anthropometric and biochemical assessments at baseline and endpoint. Serum DKK-1 levels of 92 subjects were measured at baseline and after 12-week hypoglycemic treatment.

Results: DKK-1 levels were significantly decreased after hypoglycemic treatment for 12 weeks ( < 0.001). ΔDKK-1 levels were not correlated with improvement of metabolic parameters (all > 0.05) but were negatively correlated with baseline DKK-1 levels (r = -0.263, = 0.011). Spearman correlation showed that baseline DKK-1 levels were positively related to baseline total cholesterol (r = 0.226, = 0.030) and low-density lipoprotein cholesterol (LDL-C) (r = 0.277, = 0.007). Compared with the higher baseline DKK-1 group (≥3700 pg/mL), subjects in the lower baseline DKK-1 group (<3700 pg/mL) had significantly lower baseline glycated hemoglobin A1c levels ( = 0.008) and LDL-C levels ( = 0.048). Systolic and diastolic pressure were decreased more significantly in the lower baseline DKK-1 group than that in the higher baseline DKK-1 group (both < 0.05).

Conclusion: Serum DKK-1 levels were decreased after hypoglycemic treatments. Patients with lower baseline DKK-1 levels were featured by more favorable cardiometabolic factors.

References

Zimmerman Z, Moon R, Chien A . Targeting Wnt pathways in disease. Cold Spring Harb Perspect Biol. 2012; 4(11). PMC: 3536347. DOI: 10.1101/cshperspect.a008086. View

Ghardashi-Afousi A, Davoodi M, Hesamabadi B, Asvadi-Fard M, Bigi M, Izadi M . Improved carotid intima-media thickness-induced high-intensity interval training associated with decreased serum levels of Dkk-1 and sclerostin in type 2 diabetes. J Diabetes Complications. 2019; 34(1):107469. DOI: 10.1016/j.jdiacomp.2019.107469. View

Rena G, Grahame Hardie D, Pearson E . The mechanisms of action of metformin. Diabetologia. 2017; 60(9):1577-1585. PMC: 5552828. DOI: 10.1007/s00125-017-4342-z. View

Kurban S, Eklioglu B, Selver M . Investigation of the relationship between serum sclerostin and dickkopf-1 protein levels with bone turnover in children and adolescents with type-1 diabetes mellitus. J Pediatr Endocrinol Metab. 2022; 35(5):673-679. DOI: 10.1515/jpem-2022-0001. View

Davi G, Patrono C . Platelet activation and atherothrombosis. N Engl J Med. 2007; 357(24):2482-94. DOI: 10.1056/NEJMra071014. View

Garcia-Martin A, Reyes-Garcia R, Garcia-Fontana B, Morales-Santana S, Coto-Montes A, Munoz-Garach M . Relationship of Dickkopf1 (DKK1) with cardiovascular disease and bone metabolism in Caucasian type 2 diabetes mellitus. PLoS One. 2014; 9(11):e111703. PMC: 4219763. DOI: 10.1371/journal.pone.0111703. View

Song L, Kong X, Yang Z, Zhang J, Yang W, Zhang B . Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes. Diabetes Metab Syndr Obes. 2021; 14:4451-4458. PMC: 8577516. DOI: 10.2147/DMSO.S325683. View

Wang J, Shou J, Chen X . Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene. 2000; 19(14):1843-8. DOI: 10.1038/sj.onc.1203503. View

Seifert-Held T, Pekar T, Gattringer T, Simmet N, Scharnagl H, Stojakovic T . Circulating Dickkopf-1 in acute ischemic stroke and clinically stable cerebrovascular disease. Atherosclerosis. 2011; 218(1):233-7. DOI: 10.1016/j.atherosclerosis.2011.05.015. View

10.

Stevens S, Wood S, Koshiaris C, Law K, Glasziou P, Stevens R . Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ. 2016; 354:i4098. PMC: 4979357. DOI: 10.1136/bmj.i4098. View

11.

Park K, Kwak S, Cho Y, Park K, Jang H, Kim S . Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride. J Diabetes Investig. 2016; 8(2):218-226. PMC: 5334315. DOI: 10.1111/jdi.12572. View

12.

Ueland T, Otterdal K, Lekva T, Halvorsen B, Gabrielsen A, Sandberg W . Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009; 29(8):1228-34. DOI: 10.1161/ATVBAHA.109.189761. View

13.

Ma Y, Zhang X, Wang M, Xia Q, Yang J, Wu M . The serum level of Dickkopf-1 in patients with rheumatoid arthritis: A systematic review and meta-analysis. Int Immunopharmacol. 2018; 59:227-232. DOI: 10.1016/j.intimp.2018.04.019. View

14.

Ke H, Richards W, Li X, Ominsky M . Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012; 33(5):747-83. DOI: 10.1210/er.2011-1060. View

15.

Gao F, Ma X, Peng J, Lu J, Lu W, Zhu W . The Effect of Acarbose on Glycemic Variability in Patients with Type 2 Diabetes Mellitus Using Premixed Insulin Compared to Metformin (AIM): An Open-Label Randomized Trial. Diabetes Technol Ther. 2019; 22(4):256-264. DOI: 10.1089/dia.2019.0290. View

16.

Soppert J, Lehrke M, Marx N, Jankowski J, Noels H . Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv Drug Deliv Rev. 2020; 159:4-33. DOI: 10.1016/j.addr.2020.07.019. View

17.

Huang Y, Liu L, Liu A . Dickkopf-1: Current knowledge and related diseases. Life Sci. 2018; 209:249-254. DOI: 10.1016/j.lfs.2018.08.019. View

18.

Santilli F, Liani R, Di Fulvio P, Formoso G, Simeone P, Tripaldi R . Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus. Thromb Haemost. 2016; 116(6):1089-1099. DOI: 10.1160/TH16-06-0471. View

19.

Foulquier S, Daskalopoulos E, Lluri G, Hermans K, Deb A, Blankesteijn W . WNT Signaling in Cardiac and Vascular Disease. Pharmacol Rev. 2017; 70(1):68-141. PMC: 6040091. DOI: 10.1124/pr.117.013896. View

20.

Li J, Gong W, Li X, Wan R, Mo F, Zhang Z . Recent Progress of Wnt Pathway Inhibitor Dickkopf-1 in Liver Cancer. J Nanosci Nanotechnol. 2018; 18(8):5192-5206. DOI: 10.1166/jnn.2018.14636. View